Nasdaq Cbay News Today

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on CBAY. HC Wainwright reaffirmed a neutral rating and issued a $32.50 […]

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. William Blair cut CymaBay Therapeutics from an outperform rating to a market perform […]

Jennison Associates LLC lifted its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 12.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,992,711 shares of the biopharmaceutical company’s stock after buying an additional 437,437 shares during the quarter. Jennison Associates LLC’s holdings in CymaBay Therapeutics were worth $94,308,000 at […]

Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […]

Monashee Investment Management LLC acquired a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Several other hedge funds and other […]

Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Monashee Investment […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 9,300,000 shares, a decline of 7.6% from the January 15th total of 10,070,000 shares. Based on an average trading volume of 1,710,000 shares, […]

William Blair cut shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat.com reports. William Blair also issued estimates for CymaBay Therapeutics’ FY2026 earnings at ($0.85) EPS. A number of other brokerages have also issued reports on CBAY. Lifesci Capital reaffirmed […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) – Analysts at HC Wainwright increased their FY2026 earnings estimates for shares of CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will post earnings of ($0.74) per share for the year, up from […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) – Stock analysts at William Blair issued their FY2026 earnings per share estimates for shares of CymaBay Therapeutics in a research report issued to clients and investors on Monday, February 12th. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will post earnings per share of ($0.85) […]